Global Checkpoint Inhibitors Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F Featuring AstraZeneca, Bristol-Myers Squibb, Merck & Co, Roche, Pfizer, Incyte, Novartis, and NewLink Genetics
July 29, 2022 06:23 ET
|
Research and Markets
Dublin, July 29, 2022 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2022: By Drug, By Application, By End-Users" report has been added to ResearchAndMarkets.com's offering. ...
Claudin 6: An Exceptionally Attractive Target for Drug Discovery and Development
July 25, 2022 06:53 ET
|
Research and Markets
Dublin, July 25, 2022 (GLOBE NEWSWIRE) -- The "Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering. Claudin 6...
Insights on the Natural Killer Cells Therapeutics Global Market to 2027 - by Therapeutics, Application, End-user and Region
July 01, 2022 07:13 ET
|
Research and Markets
Dublin, July 01, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Outlook on the CAR-T Cell Therapies Industry - In-depth Review of the Various Patents and Affiliated IP Documents
April 25, 2022 05:58 ET
|
Research and Markets
Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions,...
Global Car T Cell Therapy Market (2021 to 2028) - Size, Share, Outlook, and Opportunity Analysis
February 14, 2022 05:43 ET
|
Research and Markets
Dublin, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The "Car T Cell Therapy Market" report has been added to ResearchAndMarkets.com's offering. Chimeric antigen receptor (CAR) T-cell therapy is a type of...
The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis
April 06, 2021 08:45 ET
|
Roots Analysis
London, April 06, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “CAR-T Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic...
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
November 23, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
October 21, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics
June 08, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9...
Chimeric Antigen Receptor (CAR) T-cell Therapy Market to See 44.1% Annual Growth
August 14, 2018 07:00 ET
|
BCC Research
WELLESLEY, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Exciting developments in the world of immunotherapy are helping to drive incredible growth of the chimeric antigen receptor cell therapy market,...